compounded semaglutide crackdown news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Why the FDA is cracking

In addiction treatment settings specifically, patients have generally tolerated the medications well, and clinicians have reported no unexpected or severe adverse effects

2015;309:E100818

In HF, when mitochondrial oxidative metabolism and ATP synthesis decrease, it is frequently offset by an augmented glycolytic response (61)

Will new drugs lower the frequency of these side effects

The combination of rapid weight loss, nutritional changes, and potential direct medication effects can lead to thinning hair that undermines the confidence boost patients expected from their transformation

This dual action is one reason people often report stronger appetite suppression and, in clinical trials, greater weight loss compared with semaglutide